OdishaPlus Bureau

Biocon Biologics subsidiary to Biocon Ltd. will raise ₹225 crore by selling a 0.85% stake to Tata Capital Growth Fund. The minority stake sale at an equity valuation of $3.5 billion is part of a series of fund raising this fiscal year to the listing of the company.

The valuation is higher than the $3 billion valuation at which private equity fund True North had bought a 2.44% stake in the company in January. True North had acquired acquire the stake in the company for ₹536.25 crore.

In January, chief financial officer M.B. Chinappa said, “This is part of the $200-300 million round of fund raising the biologics maker plans to raise before its initial public offering. The IPO is expected within the next two years.

Biocon Biologics has raised $105 million so far. Biocon’s stake in the subsidiary is down to 95.25%.

“We appreciate the conviction of our institutional investors in the ‘value creation’ story of Biocon Biologics as a fully integrated ‘pure-play’ global biosimilars company. This equity infusion is the next step in our journey of unlocking value,” Biocon Biologics chief executive officer Christiane Hamacher said.



Please enter your comment!
Please enter your name here